Fatty Acid Oxidation Disorder Market Players:
- Ultragenyx Pharmaceutical Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Recordati Rare Diseases Inc.
- Retrophin, Inc.
- Amicus Therapeutics, Inc.
- Aeglea BioTherapeutics, Inc.
- Zogenix, Inc.
- Homology Medicines, Inc.
- Censa Pharmaceuticals Inc.
- Takeda Pharmaceutical Company Limited
- Regenxbio Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of fatty acid oxidation disorder is estimated at USD 12.35 billion.
The global fatty acid oxidation disorder market size crossed USD 11.54 billion in 2025 and is likely to register a CAGR of over 7.8%, exceeding USD 24.46 billion revenue by 2035.
Asia Pacific is projected to command a 38% share in the fatty acid oxidation disorder market by 2035, supported by rising awareness initiatives and expanding genetic testing capabilities across the region.
Key players in the market include Ultragenyx Pharmaceutical Inc., Recordati Rare Diseases Inc., Retrophin, Inc., Amicus Therapeutics, Inc., Aeglea BioTherapeutics, Inc., Zogenix, Inc.
